Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegaptanib sodium injection every 6 weeks in exudative AMD (open-label extension)
2004-004296-11Phase 2Completed
- Sponsor
- (OSI) Eyetech Pharamceuticals Inc
- Start
- Feb 2005
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegaptanib sodium in age-related macular degeneration (AMD), sponsored by (OSI) Eyetech Pharamceuticals Inc. Started Feb 2005; status: completed.
02
Drugs
pegaptanib sodium
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2004-004296-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004296-11.